SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Authors :: Choudhary, Gaurav S
Smith, Molly A
Pellagatti, Andrea
Bhagat, Tushar D
Gordon, Shanisha
Pandey, Sanjay
Shah, Nishi
Aluri, Srinivas
Booher, Robert N
Ramachandra, Murali
Samson, Maria Elena
Pradhan, Kith
Bowman, Teresa V.
Pillai, Manoj M
Guha, Chandan
Wickrema, Amittha
Will, Britta
Shastri, Aditi
Steidl, Ulrich G.
Boultwood, Jacqueline
Starczynowski, Daniel T.
Verma, Amit
Source :: Blood; November 2019, Vol. 134 Issue: Supplement 1 p4224-4224, 1p
Publication Year :: 2019
Abstract: Booher: Curis: Employment. Ramachandra:Aurigene: Employment. Samson:Curis: Employment. Will:Novartis Pharmaceuticals: Research Funding. Steidl:BayerHealthcare: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; GlaxoSmithKline: Research Funding; Celgene: Consultancy; Stelexis Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Other: Scientific Co-Founder; Pieries Pharmaceuticals: Consultancy; Aileron Therapeutics: Consultancy, Research Funding. Starczynowski:Kurome Therapeutics: Consultancy. Verma:Janssen: Research Funding; BMS: Research Funding; Celgene: Honoraria; Stelexis: Equity Ownership, Honoraria; Acceleron: Honoraria.

Full Text Access

Tools